← zu den Großinvestoren
Venrock Adviser, LLC
Vermögensverwalter · Portfolio $3.30 Mrd. · 33 Positionen · Bericht zum 30.06.2026
Aktienpositionen Bericht für 30.06.2026, eingereicht am 14.08.2026; Veränderung – ggü. 31.03.2026 · 37
| Unternehmen | Aktien | Wert | % des Portfolios | Veränderung im Quartal |
|---|---|---|---|---|
| APOGEE THERAPEUTICS INC CUSIP 03770N101 | 8 493 321 | $1.13 Mrd. | 34.18% | — |
| Oruka Therapeutics, Inc. US:ORKA | 4 148 428 | $395 Mio. | 11.97% | — |
| Erasca Inc US:ERAS | 17 891 812 | $328 Mio. | 9.94% | +1 509 000 |
| Spyre Therapeutics Inc. US:SYRE | 2 985 448 | $265 Mio. | 8.04% | −700 000 |
| Dianthus Therapeutics Inc. US:DNTH | 1 180 000 | $115 Mio. | 3.49% | — |
| Ocular Therapeutix Inc US:OCUL | 10 346 926 | $102 Mio. | 3.08% | — |
| DAMORA THERAPEUTICS INC CUSIP 36322Q206 | 3 603 595 | $93.7 Mio. | 2.84% | — |
| Savara Inc US:SVRA | 14 745 943 | $90.8 Mio. | 2.75% | +1 005 568 |
| Jade Biosciences, Inc. US:JBIO | 3 220 364 | $71.6 Mio. | 2.17% | — |
| Cogent Biosciences Inc US:COGT | 1 642 166 | $63.6 Mio. | 1.93% | −357 834 |
| Viridian Therapeutics Inc US:VRDN | 3 257 917 | $59.8 Mio. | 1.81% | −624 792 |
| Vor Biopharma Inc US:VOR | 3 041 719 | $56.0 Mio. | 1.70% | — |
| Dyne Therapeutics Inc US:DYN | 2 173 913 | $48.3 Mio. | 1.46% | — |
| Maze Therapeutics, Inc. US:MAZE | 1 602 034 | $47.8 Mio. | 1.45% | — |
| Relmada Therapeutics Inc US:RLMD | 6 844 305 | $47.4 Mio. | 1.44% | +2 000 925 |
| Oric Pharmaceuticals, Inc. US:ORIC | 4 319 765 | $46.8 Mio. | 1.42% | — |
| CRESCENT BIOPHARMA INC. CUSIP G2545C104 | 2 133 576 | $38.4 Mio. | 1.16% | — |
| ZURA BIO LTD CUSIP G9TY5A101 | 6 434 990 | $38.0 Mio. | 1.15% | — |
| Adlai Nortye Group Ltd. US:ANL | 3 212 731 | $36.9 Mio. | 1.12% | — |
| Enliven Therapeutics Inc. US:ELVN | 526 331 | $26.7 Mio. | 0.81% | −1 200 000 |
| Cybin Inc. US:HELP | 3 851 654 | $25.5 Mio. | 0.77% | — |
| Cullinan Therapeutics, Inc. US:CGEM | 1 379 965 | $25.1 Mio. | 0.76% | — |
| Century Therapeutics Inc US:IPSC | 8 695 652 | $21.3 Mio. | 0.65% | — |
| Artiva Biotherapeutics, Inc. US:ARTV | 2 043 596 | $19.8 Mio. | 0.60% | +434 027 |
| CytomX Therapeutics Inc US:CTMX | 4 982 124 | $18.7 Mio. | 0.57% | −5 000 000 |
| Achieve Life Sciences Inc US:ACHV | 2 751 032 | $18.0 Mio. | 0.54% | neu |
| Parabilis Medicines, Inc. US:PBLS | 625 000 | $17.1 Mio. | 0.52% | neu |
| Surrozen Inc US:SRZN | 632 931 | $16.4 Mio. | 0.50% | — |
| Korro Bio, Inc. US:KRRO | 1 009 500 | $13.3 Mio. | 0.40% | — |
| Alto Neuroscience, Inc. US:ANRO | 500 000 | $13.2 Mio. | 0.40% | — |
| X4 Pharmaceuticals Inc US:XFOR | 1 934 253 | $9.03 Mio. | 0.27% | +1 603 728 |
| RESEARCH ALLIANCE CORP III CUSIP G75226103 | 300 000 | $3.21 Mio. | 0.10% | neu |
| InMed Pharmaceuticals Inc US:INM | 32 685 | $50.7 Tsd. | 0.00% | neu |
| ENGENE HOLDINGS INC CUSIP 29286M105 | 0 (war 4 771 414) | — | — | verkauft |
| KALVISTA PHARMACEUTICALS INC CUSIP 483497103 | 0 (war 6 474 485) | — | — | verkauft |
| Septerna, Inc. US:SEPN | 0 (war 506 056) | — | — | verkauft |
| Tenax Therapeutics Inc US:TENX | 0 (war 1 675 262) | — | — | verkauft |
Anzeige